TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 335 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $696,000 | +302.3% | 48,624 | +283.0% | 0.03% | +300.0% |
| Q4 2021 | $173,000 | -6.5% | 12,696 | +15.3% | 0.01% | -22.2% |
| Q2 2021 | $185,000 | -29.9% | 11,016 | -23.9% | 0.01% | -35.7% |
| Q1 2021 | $264,000 | -100.0% | 14,483 | -80.5% | 0.01% | -82.3% |
| Q4 2020 | $1,352,042,000 | -49.7% | 74,288 | -50.7% | 0.08% | -54.9% |
| Q3 2020 | $2,688,399,000 | +83807.6% | 150,695 | -15.7% | 0.18% | +360.5% |
| Q2 2020 | $3,204,000 | +8.4% | 178,714 | -8.3% | 0.04% | -40.6% |
| Q1 2020 | $2,957,000 | +22.2% | 194,815 | +58.9% | 0.06% | +28.0% |
| Q4 2019 | $2,419,000 | +18.2% | 122,588 | +3.0% | 0.05% | +2.0% |
| Q3 2019 | $2,047,000 | +19.9% | 118,994 | +23.4% | 0.05% | +11.4% |
| Q2 2019 | $1,707,000 | +5.0% | 96,455 | +20.9% | 0.04% | -54.2% |
| Q1 2019 | $1,626,000 | +220.7% | 79,813 | +165.0% | 0.10% | +182.4% |
| Q4 2018 | $507,000 | – | 30,122 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 8,958,784 | $176,757,000 | 33.75% |
| Ovata Capital Management Ltd | 879,800 | $17,557,092,000 | 13.04% |
| Paulson & Co. | 13,244,711 | $261,318,000 | 5.64% |
| Glenview Capital Management | 30,582,721 | $603,397,000 | 5.28% |
| MIC CAPITAL PARTNERS (PUBLIC) (US) IM, LLC | 718,028 | $14,167,000 | 4.85% |
| Velanne Asset Management Ltd | 302,694 | $5,972,000 | 3.52% |
| Blackcrane Capital, LLC | 172,708 | $3,408,000 | 2.72% |
| Melqart Asset Management (UK) Ltd | 1,557,000 | $30,720,000 | 2.57% |
| GMT CAPITAL CORP | 3,345,976 | $66,016,000 | 2.55% |
| REDWOOD CAPITAL MANAGEMENT, LLC | 827,955 | $16,336,000 | 2.24% |